Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GB:0MGB)
LSE:0MGB
Holding GB:0MGB?
Track your performance easily
0MGB Stock Chart & Stats
Day’s Rangekr0 - kr0
52-Week Rangekr1,696.50 - kr2,637.00
Previous Closekr1,759.5
Volume14.39K
Average Volume (3M)19.85K
Market Cap
kr115.92B
Enterprise Valuekr88.55B
Total Cash (Recent Filing)kr28.14B
Total Debt (Recent Filing)kr770.00M
Price to Earnings (P/E)20.8
Beta0.77
Next Earnings
Nov 06, 2024EPS Estimate
kr21.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)84.54
Shares Outstanding65,691,573
10 Day Avg. Volume21,679
30 Day Avg. Volume19,847
Standard Deviation0.09
R-Squared0.17
Alpha0.00611
Financial Highlights & Ratios
Price to Book (P/B)42.91
Price to Sales (P/S)0.10
Price to Cash Flow (P/CF)0.90
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr2,460.00Price Target Upside39.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Genmab A/S News
Bulls Say, Bears Say
Bulls Say
Market OpportunityThe commercial opportunity in 3L+ FL represents a US TAM of $300M.
Regulatory ApprovalThe FDA granted accelerated approval for Epkinly (epcoritamab) label expansion in 3L+ FL.
Strategic DealThe deal gives Genmab worldwide rights to ProfoundBio’s novel ADC technology platforms and several preclinical and clinical candidates, most notably rinatabart sesutecan (Rina-S).
Bears Say
EarningsSignificant downside to 2025 and 2026 EBIT forecasts, with increasing operating expenses not yet captured.
Market FocusNear-term risk exists that around Q3 results, the market increases focus on 2025/26 earnings power, prompting significant downgrades and potential share price downside.
Product DevelopmentUncertainty around JNJ’s opt-in decision on HexabodyCD38, given limited data and lengthy development timelines, could lead to a double-digit share-price move.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
52.52% Mutual Funds
9.57% Other Institutional Investors
37.91% Public Companies and
Individual Investors
0MGB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest share price was kr1696.50 and its highest was kr2637.00 in the past 12 months.
What is Genmab A/S’s market cap?
Currently, no data Available
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Aug 08, 2024. The company reported kr21.7 earnings per share for the quarter, beating the consensus estimate of kr21.351 by kr0.349.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is kr21.63.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 66,176,834 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of kr21.7 in its last earnings report, beating expectations of kr21.351. Following the earnings report the stock price went down -0.137%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GB:0MGB
---
Genmab A/S Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
kr2,460.00 (39.81% Upside)
kr2,460.00 (39.81% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.64%
12-Months-Change
Fundamentals
Return on Equity
18.42%
Trailing 12-Months
Asset Growth
20.77%
Trailing 12-Months
Company Description
Genmab A/S
Genmab is a Copenhagen-based cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
---
0MGB Stock 12 Month Forecast
Average Price Target
kr2,460.00
▲(39.81% Upside)
Technical Analysis
Best Analysts Covering 0MGB
1 Year
1 Year Success Rate
18/33 ratings generated profit
1 Year Average Return
+15.50%
reiterated a buy rating last month
Copying Emily Field's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +15.50% per trade.
---